Abstract:Background: Alcoholic and hepatitis B virus (HBV)-related liver cirrhosis has placed a tremendous burden on the healthcare system with limited treatment options. This study explored the differences in the immune status of alcoholic and HBV-related liver cirrhosis. Methods: A total of 15 human liver samples from the Third Xiangya Hospital of Central South University, including five healthy controls (HC group), five alcoholic cirrhosis patients (ALC group), and five HBV-related cirrhosis patients (HBV group) were used. Of these, eight samples, including 3 HC group, 2 ALC group and 3 HBV group, were randomly collected to do single-cell RNA sequencing (scRNA-seq). The degree of steatosis was assessed by H&E staining and the presence of intrahepatic immune cells was evaluated by immunochemistry (IHC). Results: The immune status of alcoholic and HBV-related liver cirrhosis differed significantly. ScRNA-seq analysis identified a higher ratio of intrahepatic monocyte/macrophages and an obvious decreased ratio of T cells and B cells in the ALC group than in the HBV group. IHC staining of intrahepatic monocyte/macrophages, T and B cell exhibited similar results with scRNA-seq analysis. CD5L + Kupffer cells, a cell type involved in lipid metabolism, were the major monocyte/macrophage subset in ALC liver tissue. H&E staining indicated that the level of steatosis was more severe in the ALC than in the HBV group. Ligand/receptor analysis showed that the T cell exhaustion observed in the ALC liver may be related to the expression of Galectin-9 on Kupffer cells. Fewer B cells were also found in the ALC group and most had higher lipid metabolism, reduced ribosomal activity, and a dysregulated mitochondrial oxidative phosphorylation system. Moreover, scRNA-seq showed a significantly lower ratio of plasma B cells, indicating that the humoral immune response in the ALC liver was similarly dysfunctional. Ligand/receptor analysis also discovered that Galectin-9 expressed on Kupffer cells may inhibit humoral immunity. Conclusion: Patients with ALC have different immune characteristics than those with HBV-induced cirrhosis, including an increased ratio of intrahepatic monocyte/macrophages and a dysfunctional adaptive immune response in the liver. Galectin-9 could serve as a potential therapeutic target for ALC treatment.

Hepatic stellate cells and innate immunity in alcoholic liver disease

Noncoding RNAs in Alcoholic Liver Disease

Recent Insights Into the Role of Immune Cells in Alcoholic Liver Disease

Dysregulation of innate cell types in the hepatic immune microenvironment of alcoholic liver cirrhosis

Key regulators of hepatic stellate cell activation in alcohol liver Disease: A comprehensive review

Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4+ T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases

Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets

Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease

Single-cell RNA transcriptomics reveals differences in the immune status of alcoholic and hepatitis B virus-related liver cirrhosis

Alcohol and the mechanisms of liver disease

Alcoholic Hepatitis: A Review

Role of Inflammatory Factors in Development and Progression of Alcoholic Liver Disease

Targeting Inflammation for the Treatment of Alcoholic Liver Disease.

The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis

Roles of Gut Microbiota in Alcoholic Liver Disease

Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease

The role of gut microbiota, exosomes, and their interaction in the pathogenesis of ALD

Kupffer cell diversity maintains liver function in alcohol-associated liver disease

The Role of IL-17 Signaling in Regulation of the Liver–Brain Axis and Intestinal Permeability in Alcoholic Liver Disease

Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression

Alcohol and Hepatocellular Carcinoma